[go: up one dir, main page]

HUP9800743A2 - Ditiolánszármazékok és gyógyászati alkalmazásuk - Google Patents

Ditiolánszármazékok és gyógyászati alkalmazásuk

Info

Publication number
HUP9800743A2
HUP9800743A2 HU9800743A HUP9800743A HUP9800743A2 HU P9800743 A2 HUP9800743 A2 HU P9800743A2 HU 9800743 A HU9800743 A HU 9800743A HU P9800743 A HUP9800743 A HU P9800743A HU P9800743 A2 HUP9800743 A2 HU P9800743A2
Authority
HU
Hungary
Prior art keywords
con
pipe
general formula
value
atom
Prior art date
Application number
HU9800743A
Other languages
English (en)
Inventor
Takashi Fujita
Tomihisa Yokoyama
Original Assignee
Sankyo Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co., Ltd. filed Critical Sankyo Co., Ltd.
Publication of HU9800743D0 publication Critical patent/HU9800743D0/hu
Publication of HUP9800743A2 publication Critical patent/HUP9800743A2/hu
Publication of HUP9800743A3 publication Critical patent/HUP9800743A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Az (I) általánős képletű képletben ditiőlánszármazékők és gyó-gyászati készítményeként való alkalmazásűk. A képletben m és n egyikének értéke 0, a másik értéke 0, 1 vagy 2, k értéke 0 vagy 1 és 12 közötti szám R1 jelentése hidrőgénatőm, az alábbiakban meghatárőzőtt ahelyettesítők egyike vagy adőtt esetben helyettesített alkilcsőpőrt, A jelentése egyszeres vegyértékkötés, őxigénatőm, karbőnilcsőpőrt vagyegy -N(R2)CO-, -N(R2)CS-, -N(R2)SO2-, -CON(R2)N(R3)CO-, -CON(R2)CO-, -CON(R2)CS-, -CON(R2)SO2-, -O-CO-, -ON(R2)CO-, -ON(R2)SO2-,-O-CON(R2)N(R3)CO-, -O-CON(R2)CO-, -O-CON(R2)SO2-, -CO-O-, -CO-CO-, -CO-,CON(R2)N(R3)CO-, -CO-CON(R2)CO-, -CO-, -CON(R2)SO2)-, -N(R2)O-, -N(R2)COCO-, -N(R2)N(R3)CO-, -N(R2)N(R3)SO2-, -N(R2)CON(R3)N(R4)CO-, -N(R2)CON(R3)CO-, -N(R2)CON(R3)SO2- vagy -N(R2)CON(R3)SO2N(R4)CO-általánős képletű csőpőrt, B jelentése egyszeres vegyértékkötés vagy egy -N(R5)-, vagy -N(R6)N(R5)- általánős képletű csőpőrt, az a helyettesítőketarilcsőpőrtők és heterőgyűrűs csőpőrtők közül választják. A vegyületekés gyógyászatilag elfőgadható sóik azőn kiváló képességgelrendelkeznek, hőgy főkőzzák a glűtatiőn redűktáz aktivitását és ezértkülönféle betegségek, többek között hályőgők kezelésére ésmegelőzésére használhatók. ŕ
HU9800743A 1997-04-02 1998-04-01 Dithiolan derivatives, their medical use HUP9800743A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8374997 1997-04-02
JP883798 1998-01-20

Publications (3)

Publication Number Publication Date
HU9800743D0 HU9800743D0 (en) 1998-05-28
HUP9800743A2 true HUP9800743A2 (hu) 2000-05-28
HUP9800743A3 HUP9800743A3 (en) 2001-10-29

Family

ID=26343433

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9800743A HUP9800743A3 (en) 1997-04-02 1998-04-01 Dithiolan derivatives, their medical use

Country Status (23)

Country Link
US (2) US6013663A (hu)
EP (2) EP1070710A3 (hu)
KR (1) KR19980081044A (hu)
CN (1) CN1208035A (hu)
AR (1) AR012315A1 (hu)
AT (1) ATE221525T1 (hu)
AU (1) AU728488B2 (hu)
BR (1) BR9806413A (hu)
CA (1) CA2233682A1 (hu)
CZ (1) CZ96798A3 (hu)
DE (1) DE69806831T2 (hu)
DK (1) DK0869126T3 (hu)
ES (1) ES2179427T3 (hu)
HU (1) HUP9800743A3 (hu)
ID (1) ID19824A (hu)
IL (1) IL123887A0 (hu)
NO (1) NO981469L (hu)
NZ (1) NZ330092A (hu)
PL (1) PL325691A1 (hu)
PT (1) PT869126E (hu)
RU (2) RU2169731C2 (hu)
TR (2) TR199800602A2 (hu)
TW (1) TW508354B (hu)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090842A (en) * 1998-03-10 2000-07-18 The Regents Of The University Of California Lipoic acid analogs
WO2000007582A2 (en) * 1998-08-06 2000-02-17 Warner-Lambert Company Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
EP1486495B1 (en) * 1998-10-26 2009-12-09 The Research Foundation of State University of New York Salts of lipoic acid derivatives and their use in treatment of disease
DE69920260T2 (de) 1998-11-25 2005-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Antioxidationsmittel
FR2787109B1 (fr) * 1998-12-15 2001-01-19 Adir Nouveaux derives de 1,2-dithiolane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
FR2805537A1 (fr) * 2000-02-24 2001-08-31 Sod Conseils Rech Applic Nouveaux derives de l'acide lipoique, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
FR2791677B1 (fr) * 1999-04-02 2001-08-17 Sod Conseils Rech Applic Nouveaux derives de l'acide lipoique, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
AR042572A1 (es) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
IT1312569B1 (it) * 1999-05-21 2002-04-22 Raffaele Ansovini Uso dell'enzima gssg reduttasi per il trattamento terapeutico e laprofilassi di pazienti infettati da hiv.
GB9913226D0 (en) * 1999-06-07 1999-08-04 Novartis Ag Organic compounds
DE19941217A1 (de) * 1999-08-30 2001-03-15 Asta Medica Ag Behandlung der Migräne durch Verabreichung von alpha-Liponsäure oder Derivaten derselben
WO2001025226A1 (en) * 1999-10-05 2001-04-12 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
FR2806409B1 (fr) * 2000-03-16 2002-04-19 Sod Conseils Rech Applic Nouveaux derives heterocycliques de l'acide lipoique, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
CZ20023105A3 (cs) * 2000-03-16 2003-02-12 Société De Conseils De Recherches Et D'application Nové heterocyklické nebo benzenové deriváty kyseliny lipoové, jejich příprava a jejich použití jako léčiv
US6387945B2 (en) * 2000-04-11 2002-05-14 The Regents Of The University Of California Lipoic acid analogs
EP1172110A3 (de) * 2000-07-07 2003-09-17 Basf Aktiengesellschaft Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen
US8697109B2 (en) 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
US20050112113A1 (en) * 2000-08-16 2005-05-26 Till Jonathan S. Presbyopia treatment by lens alteration
US8647612B2 (en) * 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US6495170B1 (en) * 2000-08-16 2002-12-17 N. V. Nutricia Method of increasing the presence of glutathione in cells
US7914815B2 (en) * 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US8147816B2 (en) * 2000-08-16 2012-04-03 Encore Health, Llc Presbyopia treatment by lens alteration
US7935332B2 (en) * 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
IT1319196B1 (it) * 2000-10-10 2003-09-26 Laboratorio Chimico Int Spa Sintesi dell'acido r(+)alfa-lipoico.
IT1319195B1 (it) * 2000-10-10 2003-09-26 Laboratorio Chimico Int Spa Processo per la produzione dell'acido r(+)alfa-lipoico.
DE10201464B4 (de) * 2002-01-16 2005-06-16 Viatris Gmbh & Co. Kg Verfahren zur Herstellung reiner Thioctsäure
US20030187059A1 (en) * 2002-02-22 2003-10-02 Levin Robert M. Methods and compounds useful in inhibiting oxidative and/or free radical damage and in the treatment and prevention of disease
EP1480969A1 (de) * 2002-03-05 2004-12-01 Universitaet Ulm Dithiolan-derivate zur immobilisierung von biomolekülen auf edelmetallen und halbleitern
JP3970811B2 (ja) 2002-09-09 2007-09-05 独立行政法人科学技術振興機構 リンカー化合物及びリガンド、並びにそれらの製造方法
US20040229815A1 (en) * 2003-01-03 2004-11-18 Nagasawa Herbert T. Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
US7202270B2 (en) * 2003-06-20 2007-04-10 Sami Labs Limited Convenient stable non-hygroscopic crystalline solid forms of racemic and chiral LA-plus salts: process for their manufacture and uses
US7462526B2 (en) * 2003-11-18 2008-12-09 Silicon Genesis Corporation Method for fabricating semiconductor devices using strained silicon bearing material
US20080102119A1 (en) * 2006-11-01 2008-05-01 Medtronic, Inc. Osmotic pump apparatus and associated methods
US7389347B2 (en) * 2004-04-16 2008-06-17 International Business Machines Corporation Active probing for real-time diagnosis
JP2008528573A (ja) 2005-01-27 2008-07-31 アルマ マテル ストゥディオルム−ウニヴェルシタ ディ ボローニャ アルツハイマー病の処置に有用な有機化合物、それらの使用及び調製の方法
RU2292201C1 (ru) * 2005-05-30 2007-01-27 Пятигорская государственная фармацевтическая академия Композиция - мягкая лекарственная форма противоартрозного действия, содержащая диклофенак и глюкозамина гидрохлорид для ректального применения
AU2006286489B2 (en) * 2005-09-01 2012-08-09 Ares Trading S.A. Treatment of optic neuritis
CN100436444C (zh) * 2006-07-29 2008-11-26 常熟富士莱医药化工有限公司 硫辛酰胺合成工艺
US9239329B2 (en) 2006-12-18 2016-01-19 Japan Science And Technology Agency Method of measuring interaction between biomaterial and sugar chain, method of evaluating biomaterial in sugar chain selectivity, method of screening biomaterial, method of patterning biomaterials, and kits for performing these methods
JP2010520333A (ja) * 2007-03-01 2010-06-10 セダーズ−シナイ メディカル センター 〔１，２〕−ジチオラン部分を含有する抗酸化剤重合体およびその使用
KR101056039B1 (ko) * 2007-07-20 2011-08-10 (주)바이오제닉스 알파-리포일기 함유 아스코르브산 유도체 및 그의 제조방법
KR101056037B1 (ko) * 2007-07-20 2011-08-10 (주)바이오제닉스 알파-리포일기 함유 아스코르브산 유도체 및 그의 제조방법
WO2009014343A2 (en) * 2007-07-20 2009-01-29 Biogenics, Inc. Ascorbic acid derivatives having alpha-lipoyl groups and process for preparing the same
DE102007038849A1 (de) 2007-08-16 2009-02-19 Adscil Gmbh Verwendung von R(+)-alpha-Liponsäure zur Behandlung der kryptogenen Neuropathie
US8102027B2 (en) * 2007-08-21 2012-01-24 Broadcom Corporation IC package sacrificial structures for crack propagation confinement
US9028874B2 (en) * 2008-01-03 2015-05-12 Cedars-Sinai Medical Center Antioxidant nanosphere comprising [1,2]-dithiolane moieties
CN101497600B (zh) * 2008-01-29 2012-02-08 首都医科大学 2,4,5-三取代-1,3-二硫戊环、其合成方法、其应用
US9044439B2 (en) * 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
CN102088965B (zh) * 2008-05-13 2013-05-08 根梅迪卡治疗公司 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用
US8603531B2 (en) * 2008-06-02 2013-12-10 Cedars-Sinai Medical Center Nanometer-sized prodrugs of NSAIDs
FR2936146B1 (fr) 2008-09-24 2010-10-08 Oreal Utilisations de composes dithiolanes pour la photoprotection de la peau ; nouveaux composes dithiolanes ; compositions les contenant.
FR2936153B1 (fr) * 2008-09-24 2010-10-08 Oreal Utilisations de composes dithiolanes pour la photoprotection de la peau ; nouveaux composes dithiolanes ; compositions les contenant.
FR2936706B1 (fr) 2008-10-08 2010-12-17 Oreal Composition cosmetique contenant un derive de dibenzoylmethane et un compose dithiolane ; procede de photostabilisation du derive de dibenzoylmethane
FR2937035B1 (fr) * 2008-10-10 2010-12-31 Oreal Composes dithiolanes ; compositions les contenant ; utilisations pour la photoprotection de la peau
ES2529060T3 (es) 2008-11-24 2015-02-16 Cedars-Sinai Medical Center Derivados antioxidantes de la camptotecina y nanoesferas antineoplásicas antioxidantes de los mismos
FR2939042B1 (fr) * 2008-11-28 2010-11-26 Oreal PROCEDE DE DEPIGMENTATION DES MATIERES KERATINIQUES A l'AIDE DE COMPOSES DITHIOLANNES.
CN101787013B (zh) * 2009-01-22 2013-04-24 杭州民生药业有限公司 硫辛酰胺系列衍生物、制备方法及所述衍生物的制药用途
EP2408443A1 (en) * 2009-03-16 2012-01-25 Genmedica Therapeutics SL Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
EP2408441A1 (en) * 2009-03-16 2012-01-25 Genmedica Therapeutics SL Combination therapies for treating metabolic disorders
US7928067B2 (en) * 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
PT2821405E (pt) 2009-06-15 2016-06-14 Encore Health Llc Ésteres de colina para tratar a presbiopia e a catarata
PL2442647T3 (pl) 2009-06-15 2016-09-30 Związki ditiolowe, pochodne i ich zastosowania
FR2952300B1 (fr) * 2009-11-09 2012-05-11 Oreal Nouveaux colorants fluorescents a motif heterocyclique disulfure, composition de teinture les comprenant et procede de coloration des fibres keratiniques humaines a partir de ces colorants
WO2012067947A1 (en) 2010-11-18 2012-05-24 Ischemix Llc Lipoyl compounds and their use for treating ischemic injury
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
DK2920196T3 (da) 2012-11-15 2021-06-14 Univ Brandeis Binding af cysteinrester under anvendelse af cykliske disulfider
EP3110800A1 (en) * 2014-02-27 2017-01-04 Consorzio Interuniversitario Nazionale Per La Scienza E La Tecnologia Dei Materiali (INSTM) Novel compounds having anti-allodynic and antihyperalgesic activity
AU2015227307A1 (en) 2014-03-03 2016-10-13 Encore Vision, Inc. Lipoic acid choline ester compositions and methods of use
WO2016126662A1 (en) * 2015-02-03 2016-08-11 Kardiatonos, Inc. Compounds for the prevention and treatment of vascular disease
CN107614488B (zh) * 2015-03-19 2021-07-16 杭州多禧生物科技有限公司 新型亲水连接体和其在配体-药物共轭偶联物上的应用
US10711261B2 (en) 2015-08-18 2020-07-14 Brandeis University Tethering cysteine residues using cyclic disulfides
EP3429577B1 (en) * 2016-03-14 2021-12-29 NeoStrata Company, Inc. N-lipoic -amino acid or peptide, derivatives and their uses
US12435056B2 (en) 2016-03-14 2025-10-07 Neostrata Company, Inc. N-lipoic-amino acid or peptide, derivatives and their uses
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN106866620B (zh) * 2017-03-30 2019-09-20 山东齐都药业有限公司 一种硫辛酸氧化杂质的制备方法
DK3615023T3 (da) 2017-04-25 2023-09-25 Ischemix Llc Lipoyl-glu-ala til behandlingen af neurodegenerativ skade forårsaget af traumatisk hjerneskade
KR20220002965A (ko) * 2019-04-17 2022-01-07 산텐 세이야꾸 가부시키가이샤 리포산 프로드러그
CN110294738A (zh) * 2019-07-22 2019-10-01 通化师范学院 硫辛酸衍生物及其制备方法和用途
KR102701383B1 (ko) * 2022-11-11 2024-09-04 주식회사 메디치바이오 리포-하이드록삼산 유도체 및 이의 약학적 용도
WO2024101918A1 (ko) * 2022-11-11 2024-05-16 주식회사 메디치바이오 리포-하이드록삼산 유도체 및 이의 약학적 용도
GB202305212D0 (en) * 2023-04-06 2023-05-24 Elixa Mediscience Ltd Compounds
US12152174B2 (en) * 2023-04-13 2024-11-26 The Regents Of The University Of California Adjustably stable adhesive compositions for medical and non-medical uses, and recycling
CN118652428B (zh) * 2024-08-12 2024-11-19 浙江明斯特新材料有限公司 紫外光固化材料、固化聚合物材料、其制备方法及应用
US12269925B1 (en) 2024-08-13 2025-04-08 The Regents Of The University Of California Fast curing, biocompatible and biodegradable adhesives and sealants

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1210892B (de) * 1959-10-13 1966-02-17 Fujisawa Pharmaceutical Co Verfahren zur Herstellung von 5[3-(1, 2-Dithiacylopentyl)]-pentan-saeureamiden
DE1210893B (de) * 1960-06-17 1966-02-17 Fujisawa Pharmaceutical Co Verfahren zur Herstellung von 6, 8-Dithiooctansaeureamiden
FR1294134A (fr) * 1960-12-27 1962-05-26 Takeda Pharmaceutical Ind Procédé de préparation d'alpha-lipoamides
SU527432A1 (ru) * 1974-11-10 1976-09-05 Всесоюзный Научно-Исследовательский Витаминный Институт Способ получени амида липоевой кислоты
FR2541680B1 (fr) * 1983-02-24 1985-06-14 Rhone Poulenc Sante Nouveaux derives de l'amino-5 dithiole-1,2 one-3, leur preparation et les compositions medicinales qui les contiennent
CH656382A5 (de) * 1983-10-24 1986-06-30 Sandoz Ag Sulfoxide, verfahren zu ihrer herstellung und ihre verwendung.
JPH0673005B2 (ja) * 1985-01-24 1994-09-14 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
JPH0670133B2 (ja) * 1985-08-29 1994-09-07 出光興産株式会社 リポアミド膜およびその製造法
JP2553090B2 (ja) 1987-07-21 1996-11-13 帝人株式会社 組織グルタチオンレベル向上剤
DE3900649A1 (de) * 1989-01-11 1990-07-12 Boehringer Mannheim Gmbh Verfahren zur abloesung eines analyten von seinem bindeprotein
FR2653334B1 (fr) * 1989-10-19 1991-12-20 Erphar Ste Civile Preparation cosmetique de bronzage.
DE4000397A1 (de) * 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung
WO1993002076A1 (fr) * 1991-07-18 1993-02-04 Kyowa Hakko Kogyo Co., Ltd. Compose de 1,2-dithiolane
IT1252865B (it) * 1991-12-31 1995-06-28 Lifegroup Spa N-acilderivati di aminoalcooli attivi come autocoidi locali ed utilizzabili nella terapia dei processi autoimmuni
IT1256178B (it) 1992-11-30 1995-11-29 Lorenzo Ferrari Composti ad attivita' terapeutica utili per il trattamento di malattieconnesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
FR2707983A1 (fr) * 1993-07-21 1995-01-27 Pf Medicament Nouveaux dérivés de l'acide lipoïque et dihydrolipoïque, leur préparation et leur application en thérapeutique humaine.
DE4327462A1 (de) * 1993-08-16 1995-02-23 Carl Heinrich Dr Weischer Neue N-Acetyl-p-Aminophenol-Derivate zur Bekämpfung von Schmerzzuständen
DE4343593C2 (de) * 1993-12-21 1998-05-20 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz
JP2000515111A (ja) * 1995-12-14 2000-11-14 ボリソビチ バラツォフスキィ，マルク サイトカインおよび造血因子の内因性産生増強因子とその利用方法

Also Published As

Publication number Publication date
NO981469L (no) 1998-10-05
IL123887A0 (en) 1998-10-30
AU728488B2 (en) 2001-01-11
EP1070710A3 (en) 2001-03-21
EP0869126A1 (en) 1998-10-07
TR199800602A3 (tr) 1999-10-21
HUP9800743A3 (en) 2001-10-29
TR199800602A2 (xx) 1999-10-21
US6013663A (en) 2000-01-11
TR200202678A2 (tr) 2004-01-21
CZ96798A3 (cs) 1998-10-14
DE69806831D1 (de) 2002-09-05
DK0869126T3 (da) 2002-11-18
ATE221525T1 (de) 2002-08-15
MX9802679A (es) 1998-12-31
KR19980081044A (ko) 1998-11-25
DE69806831T2 (de) 2003-03-27
HK1015765A1 (en) 1999-10-22
HU9800743D0 (en) 1998-05-28
PL325691A1 (en) 1998-10-12
CN1208035A (zh) 1999-02-17
ES2179427T3 (es) 2003-01-16
RU2165932C2 (ru) 2001-04-27
NO981469D0 (no) 1998-04-01
TW508354B (en) 2002-11-01
CA2233682A1 (en) 1998-10-02
ID19824A (id) 1998-08-06
RU99119545A (ru) 2004-03-27
US6313164B1 (en) 2001-11-06
AR012315A1 (es) 2000-10-18
NZ330092A (en) 1999-04-29
RU2169731C2 (ru) 2001-06-27
EP1070710A2 (en) 2001-01-24
PT869126E (pt) 2002-10-31
EP0869126B1 (en) 2002-07-31
AU5970298A (en) 1998-10-08
BR9806413A (pt) 2003-04-15

Similar Documents

Publication Publication Date Title
HUP9800743A2 (hu) Ditiolánszármazékok és gyógyászati alkalmazásuk
ATE60761T1 (de) Chinazolinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE69930926D1 (de) Benzolsulfonamid-derivate und ihre anwendung als arzneimittel
HUP0004529A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk
HUP0004259A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények
CA2000985A1 (en) 1,4-diazepine derivative and its pharmaceutical use
NO905572L (no) Fremgangsmaate for fremstilling av peptidforbindelser.
CA2369560A1 (en) Agent for prophylaxis and treatment of liver disease
HUP9902017A2 (hu) Aminosav- és hidroxisav-származékokkal szubsztituált benzamidinszármazékok és antikoagulánsokként történő alkalmazásuk
HUP9801356A2 (hu) Triciklusos (2-hidroxi-2-metil-3,3,3-trifluor-propanoil)-amino-benzoxepin-, -benzotiepin-, -benzocikloheptén-, -indén-származékok és az ezeket tartalmazó gyógyszerkészítmények
DE69101835D1 (de) N-phenyl-n-acetamidoglycinamide, ihre herstellung und medikamente, die sie enthalten.
IE872588L (en) Compounds
ATE38991T1 (de) In 2-stellung substituierte 1,3propyledendephosphonat-derivate, ihre herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
ATE156119T1 (de) 2-formylpyridin-thiosemicarbazonderivate, ihre herstellung und ihre verwendung als antitumor mittel
NO873272L (no) Fremgangsmaate for fremstilling av fenoxyeddiksyrederivater
JPS6450819A (en) Antidementia agent
ATE21101T1 (de) N-iminopyridinium-betain-derivate, ihre herstellung und ihre verwendung als arzneimittel.
HUP9902149A2 (hu) Antibakteriális hatású 1-metil-karbapenem-származékok, alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények
HUP9802348A2 (hu) 2-Fenil-3-aroil-benzotiofének alkalmazása plazminogén aktivátor inhibitor-1 gátló hatású gyógyszerkészítmények előállítására
HUP9901969A2 (hu) N-(merkapto-alkanoil)-cisztein-származékok alkalmazása ischemia kezelésére szolgáló gyógyszerkészítmények előállítására
DE69231350D1 (de) Indolizinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
NO173010C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktivt sulfonanilid
HUP9904402A2 (hu) Polihidroxi-fenol-származékok, alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
NO903084L (no) Farmasoeytisk anvendbare thiazolderivater og fremgangsmaatefor deresfremstilling.
HUP9801985A2 (hu) Cisztinszármazékok alkalmazása restenózis gyógyítására használható gyógyszerkészítmények előállítására